1
|
Travisano SI, Harrison MRM, Thornton ME, Grubbs BH, Quertermous T, Lien CL. Single-nuclei multiomic analyses identify human cardiac lymphatic endothelial cells associated with coronary arteries in the epicardium. Cell Rep 2023; 42:113106. [PMID: 37676760 DOI: 10.1016/j.celrep.2023.113106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 07/31/2023] [Accepted: 08/23/2023] [Indexed: 09/09/2023] Open
Abstract
Cardiac lymphatic vessels play important roles in fluid homeostasis, inflammation, disease, and regeneration of the heart. The developing cardiac lymphatics in human fetal hearts are closely associated with coronary arteries, similar to those in zebrafish hearts. We identify a population of cardiac lymphatic endothelial cells (LECs) that reside in the epicardium. Single-nuclei multiomic analysis of the human fetal heart reveals the plasticity and heterogeneity of the cardiac endothelium. Furthermore, we find that VEGFC is highly expressed in arterial endothelial cells and epicardium-derived cells, providing a molecular basis for the arterial association of cardiac lymphatic development. Using a cell-type-specific integrative analysis, we identify a population of cardiac lymphatic endothelial cells marked by the PROX1 and the lymphangiocrine RELN and enriched in binding motifs of erythroblast transformation specific (ETS) variant (ETV) transcription factors. We report the in vivo molecular characterization of human cardiac lymphatics and provide a valuable resource to understand fetal heart development.
Collapse
Affiliation(s)
| | - Michael R M Harrison
- The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA 90027, USA; Cardiovascular Research Institute, Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY 10021, USA
| | - Matthew E Thornton
- Maternal-Fetal Medicine Division, Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Brendan H Grubbs
- Maternal-Fetal Medicine Division, Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Thomas Quertermous
- Division of Cardiovascular Medicine and the Cardiovascular Institute, School of Medicine, Stanford University, Falk CVRC, Stanford, CA 94305, USA
| | - Ching-Ling Lien
- The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA 90027, USA; Departments of Surgery, Biochemistry, and Molecular Medicine, Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
| |
Collapse
|
2
|
Chen D, Forghany Z, Liu X, Wang H, Merks RMH, Baker DA. A new model of Notch signalling: Control of Notch receptor cis-inhibition via Notch ligand dimers. PLoS Comput Biol 2023; 19:e1010169. [PMID: 36668673 PMCID: PMC9891537 DOI: 10.1371/journal.pcbi.1010169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 02/01/2023] [Accepted: 12/30/2022] [Indexed: 01/22/2023] Open
Abstract
All tissue development and replenishment relies upon the breaking of symmetries leading to the morphological and operational differentiation of progenitor cells into more specialized cells. One of the main engines driving this process is the Notch signal transduction pathway, a ubiquitous signalling system found in the vast majority of metazoan cell types characterized to date. Broadly speaking, Notch receptor activity is governed by a balance between two processes: 1) intercellular Notch transactivation triggered via interactions between receptors and ligands expressed in neighbouring cells; 2) intracellular cis inhibition caused by ligands binding to receptors within the same cell. Additionally, recent reports have also unveiled evidence of cis activation. Whilst context-dependent Notch receptor clustering has been hypothesized, to date, Notch signalling has been assumed to involve an interplay between receptor and ligand monomers. In this study, we demonstrate biochemically, through a mutational analysis of DLL4, both in vitro and in tissue culture cells, that Notch ligands can efficiently self-associate. We found that the membrane proximal EGF-like repeat of DLL4 was necessary and sufficient to promote oligomerization/dimerization. Mechanistically, our experimental evidence supports the view that DLL4 ligand dimerization is specifically required for cis-inhibition of Notch receptor activity. To further substantiate these findings, we have adapted and extended existing ordinary differential equation-based models of Notch signalling to take account of the ligand dimerization-dependent cis-inhibition reported here. Our new model faithfully recapitulates our experimental data and improves predictions based upon published data. Collectively, our work favours a model in which net output following Notch receptor/ligand binding results from ligand monomer-driven Notch receptor transactivation (and cis activation) counterposed by ligand dimer-mediated cis-inhibition.
Collapse
Affiliation(s)
- Daipeng Chen
- School of Mathematics and Statistics, Xi’an Jiaotong University, Xi’an, China
- Mathematical Institute, Leiden University, Leiden, The Netherlands
| | - Zary Forghany
- Leiden University Medical Center (LUMC), Department of Cell & Chemical Biology, Leiden, The Netherlands
| | - Xinxin Liu
- Leiden University Medical Center (LUMC), Department of Cell & Chemical Biology, Leiden, The Netherlands
| | - Haijiang Wang
- Leiden University Medical Center (LUMC), Department of Cell & Chemical Biology, Leiden, The Netherlands
- Department of General Surgery, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China
| | - Roeland M. H. Merks
- Mathematical Institute, Leiden University, Leiden, The Netherlands
- Institute of Biology Leiden, Leiden University, Leiden, The Netherlands
- * E-mail: (RMHM); (DAB)
| | - David A. Baker
- Leiden University Medical Center (LUMC), Department of Cell & Chemical Biology, Leiden, The Netherlands
- * E-mail: (RMHM); (DAB)
| |
Collapse
|
3
|
The Evolution of Biomineralization through the Co-Option of Organic Scaffold Forming Networks. Cells 2022; 11:cells11040595. [PMID: 35203246 PMCID: PMC8870065 DOI: 10.3390/cells11040595] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Revised: 02/07/2022] [Accepted: 02/08/2022] [Indexed: 12/05/2022] Open
Abstract
Biomineralization is the process in which organisms use minerals to generate hard structures like teeth, skeletons and shells. Biomineralization is proposed to have evolved independently in different phyla through the co-option of pre-existing developmental programs. Comparing the gene regulatory networks (GRNs) that drive biomineralization in different species could illuminate the molecular evolution of biomineralization. Skeletogenesis in the sea urchin embryo was extensively studied and the underlying GRN shows high conservation within echinoderms, larval and adult skeletogenesis. The organic scaffold in which the calcite skeletal elements form in echinoderms is a tubular compartment generated by the syncytial skeletogenic cells. This is strictly different than the organic cartilaginous scaffold that vertebrates mineralize with hydroxyapatite to make their bones. Here I compare the GRNs that drive biomineralization and tubulogenesis in echinoderms and in vertebrates. The GRN that drives skeletogenesis in the sea urchin embryo shows little similarity to the GRN that drives bone formation and high resemblance to the GRN that drives vertebrates’ vascular tubulogenesis. On the other hand, vertebrates’ bone-GRNs show high similarity to the GRNs that operate in the cells that generate the cartilage-like tissues of basal chordate and invertebrates that do not produce mineralized tissue. These comparisons suggest that biomineralization in deuterostomes evolved through the phylum specific co-option of GRNs that control distinct organic scaffolds to mineralization.
Collapse
|
4
|
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors. Cancers (Basel) 2021; 13:cancers13122951. [PMID: 34204675 PMCID: PMC8231556 DOI: 10.3390/cancers13122951] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 06/07/2021] [Accepted: 06/09/2021] [Indexed: 01/05/2023] Open
Abstract
Angiogenesis, i.e., the formation of new blood vessels from pre-existing endothelial cell (EC)-lined vessels, is critical for tissue development and also contributes to neovascularization-related diseases, such as cancer. Vascular endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs) are among many secreted cytokines that regulate EC function. While several pharmacological anti-angiogenic agents have reached the clinic, further improvement is needed to increase clinical efficacy and to overcome acquired therapy resistance. More insights into the functional consequences of targeting specific pathways that modulate blood vessel formation may lead to new therapeutic approaches. Here, we synthesized and identified two macrocyclic small molecular compounds termed OD16 and OD29 that inhibit BMP type I receptor (BMPRI)-induced SMAD1/5 phosphorylation and downstream gene expression in ECs. Of note, OD16 and OD29 demonstrated higher specificity against BMPRI activin receptor-like kinase 1/2 (ALK1/2) than the commonly used small molecule BMPRI kinase inhibitor LDN-193189. OD29, but not OD16, also potently inhibited VEGF-induced extracellular regulated kinase MAP kinase phosphorylation in ECs. In vitro, OD16 and OD29 exerted strong inhibition of BMP9 and VEGF-induced ECs migration, invasion and cord formation. Using Tg (fli:EGFP) zebrafish embryos, we found that OD16 and OD29 potently antagonized dorsal longitudinal anastomotic vessel (DLAV), intra segmental vessel (ISV), and subintestinal vessel (SIV) formation during embryonic development. Moreover, the MDA-MB-231 breast cancer cell-induced tumor angiogenesis in zebrafish embryos was significantly decreased by OD16 and OD29. Both macrocyclic compounds might provide a steppingstone for the development of novel anti-angiogenesis therapeutic agents.
Collapse
|
5
|
Duddu S, Chakrabarti R, Ghosh A, Shukla PC. Hematopoietic Stem Cell Transcription Factors in Cardiovascular Pathology. Front Genet 2020; 11:588602. [PMID: 33193725 PMCID: PMC7596349 DOI: 10.3389/fgene.2020.588602] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Accepted: 09/21/2020] [Indexed: 12/14/2022] Open
Abstract
Transcription factors as multifaceted modulators of gene expression that play a central role in cell proliferation, differentiation, lineage commitment, and disease progression. They interact among themselves and create complex spatiotemporal gene regulatory networks that modulate hematopoiesis, cardiogenesis, and conditional differentiation of hematopoietic stem cells into cells of cardiovascular lineage. Additionally, bone marrow-derived stem cells potentially contribute to the cardiovascular cell population and have shown potential as a therapeutic approach to treat cardiovascular diseases. However, the underlying regulatory mechanisms are currently debatable. This review focuses on some key transcription factors and associated epigenetic modifications that modulate the maintenance and differentiation of hematopoietic stem cells and cardiac progenitor cells. In addition to this, we aim to summarize different potential clinical therapeutic approaches in cardiac regeneration therapy and recent discoveries in stem cell-based transplantation.
Collapse
Affiliation(s)
| | | | | | - Praphulla Chandra Shukla
- School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India
| |
Collapse
|
6
|
Page DJ, Thuret R, Venkatraman L, Takahashi T, Bentley K, Herbert SP. Positive Feedback Defines the Timing, Magnitude, and Robustness of Angiogenesis. Cell Rep 2019; 27:3139-3151.e5. [PMID: 31189101 PMCID: PMC6581738 DOI: 10.1016/j.celrep.2019.05.052] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 04/01/2019] [Accepted: 05/15/2019] [Indexed: 12/20/2022] Open
Abstract
Angiogenesis is driven by the coordinated collective branching of specialized leading "tip" and trailing "stalk" endothelial cells (ECs). While Notch-regulated negative feedback suppresses excessive tip selection, roles for positive feedback in EC identity decisions remain unexplored. Here, by integrating computational modeling with in vivo experimentation, we reveal that positive feedback critically modulates the magnitude, timing, and robustness of angiogenic responses. In silico modeling predicts that positive-feedback-mediated amplification of VEGF signaling generates an ultrasensitive bistable switch that underpins quick and robust tip-stalk decisions. In agreement, we define a positive-feedback loop exhibiting these properties in vivo, whereby Vegf-induced expression of the atypical tetraspanin, tm4sf18, amplifies Vegf signaling to dictate the speed and robustness of EC selection for angiogenesis. Consequently, tm4sf18 mutant zebrafish select fewer motile ECs and exhibit stunted hypocellular vessels with unstable tip identity that is severely perturbed by even subtle Vegfr attenuation. Hence, positive feedback spatiotemporally shapes the angiogenic switch to ultimately modulate vascular network topology.
Collapse
Affiliation(s)
- Donna J Page
- Faculty of Biology, Medicine and Health, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK; School of Healthcare Science, Manchester Metropolitan University, Manchester M1 5GD, UK
| | - Raphael Thuret
- Faculty of Biology, Medicine and Health, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK
| | - Lakshmi Venkatraman
- Biomedical Engineering Department, Boston University, 610 Commonwealth Avenue, Boston, MA 02215, USA; Immunology, Genetics and Pathology Department, University of Uppsala, 751 85 Uppsala, Sweden
| | - Tokiharu Takahashi
- Faculty of Biology, Medicine and Health, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK
| | - Katie Bentley
- Biomedical Engineering Department, Boston University, 610 Commonwealth Avenue, Boston, MA 02215, USA; Immunology, Genetics and Pathology Department, University of Uppsala, 751 85 Uppsala, Sweden; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Cellular Adaptive Behaviour Lab, The Francis Crick Institute, Midland Road, London NW1 1AT, UK; Department of Informatics, Faculty of Natural and Mathematical Sciences, King's College London, Strand Campus, London WC2B 4BG, UK.
| | - Shane P Herbert
- Faculty of Biology, Medicine and Health, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK.
| |
Collapse
|
7
|
Possible cooption of a VEGF-driven tubulogenesis program for biomineralization in echinoderms. Proc Natl Acad Sci U S A 2019; 116:12353-12362. [PMID: 31152134 DOI: 10.1073/pnas.1902126116] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Biomineralization is the process by which living organisms use minerals to form hard structures that protect and support them. Biomineralization is believed to have evolved rapidly and independently in different phyla utilizing preexisting components. The mechanistic understanding of the regulatory networks that drive biomineralization and their evolution is far from clear. Sea urchin skeletogenesis is an excellent model system for studying both gene regulation and mineral uptake and deposition. The sea urchin calcite spicules are formed within a tubular cavity generated by the skeletogenic cells controlled by vascular endothelial growth factor (VEGF) signaling. The VEGF pathway is essential for biomineralization in echinoderms, while in many other phyla, across metazoans, it controls tubulogenesis and vascularization. Despite the critical role of VEGF signaling in sea urchin spiculogenesis, the downstream program it activates was largely unknown. Here we study the cellular and molecular machinery activated by the VEGF pathway during sea urchin spiculogenesis and reveal multiple parallels to the regulation of vertebrate vascularization. Human VEGF rescues sea urchin VEGF knockdown, vesicle deposition into an internal cavity plays a significant role in both systems, and sea urchin VEGF signaling activates hundreds of genes, including biomineralization and interestingly, vascularization genes. Moreover, five upstream transcription factors and three signaling genes that drive spiculogenesis are homologous to vertebrate factors that control vascularization. Overall, our findings suggest that sea urchin spiculogenesis and vertebrate vascularization diverged from a common ancestral tubulogenesis program, broadly adapted for vascularization and specifically coopted for biomineralization in the echinoderm phylum.
Collapse
|
8
|
Eelen G, de Zeeuw P, Treps L, Harjes U, Wong BW, Carmeliet P. Endothelial Cell Metabolism. Physiol Rev 2018; 98:3-58. [PMID: 29167330 PMCID: PMC5866357 DOI: 10.1152/physrev.00001.2017] [Citation(s) in RCA: 330] [Impact Index Per Article: 55.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Revised: 06/19/2017] [Accepted: 06/22/2017] [Indexed: 02/06/2023] Open
Abstract
Endothelial cells (ECs) are more than inert blood vessel lining material. Instead, they are active players in the formation of new blood vessels (angiogenesis) both in health and (life-threatening) diseases. Recently, a new concept arose by which EC metabolism drives angiogenesis in parallel to well-established angiogenic growth factors (e.g., vascular endothelial growth factor). 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3-driven glycolysis generates energy to sustain competitive behavior of the ECs at the tip of a growing vessel sprout, whereas carnitine palmitoyltransferase 1a-controlled fatty acid oxidation regulates nucleotide synthesis and proliferation of ECs in the stalk of the sprout. To maintain vascular homeostasis, ECs rely on an intricate metabolic wiring characterized by intracellular compartmentalization, use metabolites for epigenetic regulation of EC subtype differentiation, crosstalk through metabolite release with other cell types, and exhibit EC subtype-specific metabolic traits. Importantly, maladaptation of EC metabolism contributes to vascular disorders, through EC dysfunction or excess angiogenesis, and presents new opportunities for anti-angiogenic strategies. Here we provide a comprehensive overview of established as well as newly uncovered aspects of EC metabolism.
Collapse
Affiliation(s)
- Guy Eelen
- Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium; and Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium
| | - Pauline de Zeeuw
- Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium; and Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium
| | - Lucas Treps
- Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium; and Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium
| | - Ulrike Harjes
- Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium; and Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium
| | - Brian W Wong
- Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium; and Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium
| | - Peter Carmeliet
- Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium; and Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium
| |
Collapse
|
9
|
Forghany Z, Robertson F, Lundby A, Olsen JV, Baker DA. Control of endothelial cell tube formation by Notch ligand intracellular domain interactions with activator protein 1 (AP-1). J Biol Chem 2017; 293:1229-1242. [PMID: 29196606 DOI: 10.1074/jbc.m117.819045] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 11/30/2017] [Indexed: 01/08/2023] Open
Abstract
Notch signaling is a ubiquitous signal transduction pathway found in most if not all metazoan cell types characterized to date. It is indispensable for cell differentiation as well as tissue growth, tissue remodeling, and apoptosis. Although the canonical Notch signaling pathway is well characterized, accumulating evidence points to the existence of multiple, less well-defined layers of regulation. In this study, we investigated the function of the intracellular domain (ICD) of the Notch ligand Delta-like 4 (DLL4). We provide evidence that the DLL4 ICD is required for normal DLL4 subcellular localization. We further show that it is cleaved and interacts with the JUN proto-oncogene, which forms part of the activator protein 1 (AP-1) transcription factor complex. Mechanistically, the DLL4 ICD inhibited JUN binding to DNA and thereby controlled the expression of JUN target genes, including DLL4 Our work further demonstrated that JUN strongly stimulates endothelial cell tube formation and that DLL4 constrains this process. These results raise the possibility that Notch/DLL4 signaling is bidirectional and suggest that the DLL4 ICD could represent a point of cross-talk between Notch and receptor tyrosine kinase (RTK) signaling.
Collapse
Affiliation(s)
- Zary Forghany
- From the Department of Molecular Cell Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands and
| | - Francesca Robertson
- From the Department of Molecular Cell Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands and
| | - Alicia Lundby
- Novo Nordisk Foundation Center for Protein Research and.,the Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark
| | | | - David A Baker
- From the Department of Molecular Cell Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands and
| |
Collapse
|
10
|
van IJzendoorn DGP, Forghany Z, Liebelt F, Vertegaal AC, Jochemsen AG, Bovée JVMG, Szuhai K, Baker DA. Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis. J Biol Chem 2017; 292:21282-21290. [PMID: 29150442 DOI: 10.1074/jbc.c117.815845] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 11/03/2017] [Indexed: 11/06/2022] Open
Abstract
Epithelioid hemangioma is a locally aggressive vascular neoplasm, found in bones and soft tissue, whose cause is currently unknown, but may involve oncogene activation. FOS is one of the earliest viral oncogenes to be characterized, and normal cellular FOS forms part of the activator protein 1 (AP-1) transcription factor complex, which plays a pivotal role in cell growth, differentiation, and survival as well as the DNA damage response. Despite this, a causal link between aberrant FOS function and naturally occurring tumors has not yet been established. Here, we describe a thorough molecular and biochemical analysis of a mutant FOS protein we identified in these vascular tumors. The mutant protein lacks a highly conserved helix consisting of the C-terminal four amino acids of FOS, which we show is indispensable for fast, ubiquitin-independent FOS degradation via the 20S proteasome. Our work reveals that FOS stimulates endothelial sprouting and that perturbation of normal FOS degradation could account for the abnormal vessel growth typical of epithelioid hemangioma. To the best of our knowledge, this is the first functional characterization of mutant FOS proteins found in tumors.
Collapse
Affiliation(s)
| | - Zary Forghany
- Molecular Cell Biology, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands
| | - Frauke Liebelt
- Molecular Cell Biology, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands
| | - Alfred C Vertegaal
- Molecular Cell Biology, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands
| | - Aart G Jochemsen
- Molecular Cell Biology, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands
| | | | - Karoly Szuhai
- Molecular Cell Biology, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands
| | - David A Baker
- Molecular Cell Biology, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands
| |
Collapse
|
11
|
Rasighaemi P, Ward AC. ETV6 and ETV7: Siblings in hematopoiesis and its disruption in disease. Crit Rev Oncol Hematol 2017; 116:106-115. [PMID: 28693791 DOI: 10.1016/j.critrevonc.2017.05.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 05/05/2017] [Accepted: 05/28/2017] [Indexed: 01/07/2023] Open
Abstract
ETV6 (TEL1) and ETV7 (TEL2) are closely-related members of the ETS family of transcriptional regulators. Both ETV6 and ETV7 have been demonstrated to play key roles in hematopoiesis, particularly with regard to maintenance of hematopoietic stem cells and control of lineage-specific differentiation, with evidence of functional interactions between both proteins. ETV6 has been strongly implicated in the molecular etiology of a number of hematopoietic diseases, including as a tumor suppressor, an oncogenic fusion partner, and an important regulator of thrombopoiesis, but recent evidence has also identified ETV7 as a potential oncogene in certain malignancies. This review provides an overview of ETV6 and ETV7 and their contribution to both normal and disrupted hematopoiesis. It also highlights the key clinical implications of the growing knowledge base regarding ETV6 abnormalities with respect to prognosis and treatment.
Collapse
Affiliation(s)
- Parisa Rasighaemi
- School of Medicine and Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria, 3216, Australia.
| | - Alister C Ward
- School of Medicine and Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria, 3216, Australia.
| |
Collapse
|
12
|
Benn A, Hiepen C, Osterland M, Schütte C, Zwijsen A, Knaus P. Role of bone morphogenetic proteins in sprouting angiogenesis: differential BMP receptor-dependent signaling pathways balance stalk vs. tip cell competence. FASEB J 2017; 31:4720-4733. [PMID: 28733457 PMCID: PMC5636702 DOI: 10.1096/fj.201700193rr] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Accepted: 06/27/2017] [Indexed: 01/04/2023]
Abstract
Before the onset of sprouting angiogenesis, the endothelium is prepatterned for the positioning of tip and stalk cells. Both cell identities are not static, as endothelial cells (ECs) constantly compete for the tip cell position in a dynamic fashion. Here, we show that both bone morphogenetic protein 2 (BMP2) and BMP6 are proangiogenic in vitro and ex vivo and that the BMP type I receptors, activin receptor-like kinase 3 (ALK3) and ALK2, play crucial and distinct roles in this process. BMP2 activates the expression of tip cell-associated genes, such as delta-like ligand 4 (DLL4) and kinase insert domain receptor (KDR), and p38-heat shock protein 27 (HSP27)-dependent cell migration, thereby generating tip cell competence. Whereas BMP6 also triggers collective cell migration via the p38-HSP27 signaling axis, BMP6 induces in addition SMAD1/5 signaling, thereby promoting the expression of stalk cell-associated genes, such as hairy and enhancer of split 1 (HES1) and fms-like tyrosine kinase 1 (FLT1). Specifically, ALK3 is required for sprouting from HUVEC spheroids, whereas ALK2 represses sprout formation. We demonstrate that expression levels and respective complex formation of BMP type I receptors in ECs determine stalk vs. tip cell identity, thus contributing to endothelial plasticity during sprouting angiogenesis. As antiangiogenic monotherapies that target the VEGF or ALK1 pathways have not fulfilled efficacy objectives in clinical trials, the selective targeting of the ALK2/3 pathways may be an attractive new approach.-Benn, A., Hiepen, C., Osterland, M., Schütte, C., Zwijsen, A., Knaus, P. Role of bone morphogenetic proteins in sprouting angiogenesis: differential BMP receptor-dependent signaling pathways balance stalk vs. tip cell competence.
Collapse
Affiliation(s)
- Andreas Benn
- Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.,Deutsche Forschungsgemeinschaft (DFG) Graduate School 1093, Berlin School of Integrative Oncology, Berlin, Germany.,DFG Graduate School 203, Berlin-Brandenburg School for Regenerative Therapies, Berlin, Germany.,Vlaams Instituut voor Biotechnologie (VIB) Center for Brain and Disease Research, KU Leuven, Leuven, Belgium.,Department of Human Genetics, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Christian Hiepen
- Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.,DFG Graduate School 203, Berlin-Brandenburg School for Regenerative Therapies, Berlin, Germany
| | - Marc Osterland
- Zuse Institute Berlin, Berlin, Germany.,Institute for Mathematics, Freie Universität Berlin, Berlin, Germany
| | - Christof Schütte
- Zuse Institute Berlin, Berlin, Germany.,Institute for Mathematics, Freie Universität Berlin, Berlin, Germany
| | - An Zwijsen
- Vlaams Instituut voor Biotechnologie (VIB) Center for Brain and Disease Research, KU Leuven, Leuven, Belgium.,Department of Human Genetics, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Petra Knaus
- Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany; .,Deutsche Forschungsgemeinschaft (DFG) Graduate School 1093, Berlin School of Integrative Oncology, Berlin, Germany.,DFG Graduate School 203, Berlin-Brandenburg School for Regenerative Therapies, Berlin, Germany
| |
Collapse
|
13
|
Xuan Q, Zhong X, Li W, Mo Z, Huang Y, Hu Y. CtBP2 is associated with angiogenesis and regulates the apoptosis of prostate cancer cells. Oncol Rep 2017; 38:1259-1267. [PMID: 28677795 DOI: 10.3892/or.2017.5763] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Accepted: 05/08/2017] [Indexed: 11/06/2022] Open
Abstract
Angiogenesis is associated with prostate cancer (PCa) development and progression. Aberrant expression of C-terminal binding protein (CtBP)2 has been observed in PCa, but whether its change in expression plays a significant role in angiogenesis has not been completely characterized. we attempted to integrate and analyze the genome-wide association study (GWAS) of follicle stimulating hormone receptor (FSHR) and CtBP2, the Cancer Genome Atlas (TCGA) data and CtBP2 binding data in CistromeMap (18) to explore the mechanism of CtBP2 in PCa, and performed pathway enrichment analysis. We revealed that the top 6 pathways were closely related with angiogenesis. We used siRNA and overexpression plasmids to silence and overexpress CtBP2 expression. Altered expression of CtBP2 affected the expression of VEGFA, FSHR, FHL2 and SMAD3 which are closely related with angiogenesis. In addition, silencing of CtBP2 markedly increased the apoptosis of PCa cells in vitro, and decreased the expression of IL-8, AT2R, CCND1 and MMP9 which are associated with cancer progression. These results highlight the association between CtBP2 and angiogenesis in PCa and indicate that CtBP2 may be a potential therapeutic target for PCa.
Collapse
Affiliation(s)
- Qiang Xuan
- Department of Urology, Anhui Provincial Hospital Affiliated Anhui Medical University, Hefei, Anhui 230022, P.R. China
| | - Xiaoge Zhong
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
| | - Weidong Li
- Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
| | - Zengnan Mo
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
| | - Yuanjie Huang
- Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
| | - Yanling Hu
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
| |
Collapse
|
14
|
Fish JE, Cantu Gutierrez M, Dang LT, Khyzha N, Chen Z, Veitch S, Cheng HS, Khor M, Antounians L, Njock MS, Boudreau E, Herman AM, Rhyner AM, Ruiz OE, Eisenhoffer GT, Medina-Rivera A, Wilson MD, Wythe JD. Dynamic regulation of VEGF-inducible genes by an ERK/ERG/p300 transcriptional network. Development 2017; 144:2428-2444. [PMID: 28536097 DOI: 10.1242/dev.146050] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Accepted: 05/15/2017] [Indexed: 12/20/2022]
Abstract
The transcriptional pathways activated downstream of vascular endothelial growth factor (VEGF) signaling during angiogenesis remain incompletely characterized. By assessing the signals responsible for induction of the Notch ligand delta-like 4 (DLL4) in endothelial cells, we find that activation of the MAPK/ERK pathway mirrors the rapid and dynamic induction of DLL4 transcription and that this pathway is required for DLL4 expression. Furthermore, VEGF/ERK signaling induces phosphorylation and activation of the ETS transcription factor ERG, a prerequisite for DLL4 induction. Transcription of DLL4 coincides with dynamic ERG-dependent recruitment of the transcriptional co-activator p300. Genome-wide gene expression profiling identified a network of VEGF-responsive and ERG-dependent genes, and ERG chromatin immunoprecipitation (ChIP)-seq revealed the presence of conserved ERG-bound putative enhancer elements near these target genes. Functional experiments performed in vitro and in vivo confirm that this network of genes requires ERK, ERG and p300 activity. Finally, genome-editing and transgenic approaches demonstrate that a highly conserved ERG-bound enhancer located upstream of HLX (which encodes a transcription factor implicated in sprouting angiogenesis) is required for its VEGF-mediated induction. Collectively, these findings elucidate a novel transcriptional pathway contributing to VEGF-dependent angiogenesis.
Collapse
Affiliation(s)
- Jason E Fish
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada .,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Manuel Cantu Gutierrez
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX 77030, USA.,Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030, USA.,Graduate Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Lan T Dang
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Nadiya Khyzha
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Zhiqi Chen
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Shawn Veitch
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Henry S Cheng
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Melvin Khor
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Lina Antounians
- Genetics and Genome Biology, Hospital for Sick Children, Toronto M5G 0A4, Canada.,Department of Molecular Genetics, University of Toronto, Toronto M5S 1A8, Canada
| | - Makon-Sébastien Njock
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Emilie Boudreau
- Toronto General Hospital Research Institute, University Health Network, Toronto M5G 2C4, Canada.,Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5S 1A8, Canada.,Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada
| | - Alexander M Herman
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX 77030, USA.,Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Alexander M Rhyner
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX 77030, USA.,Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Oscar E Ruiz
- Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - George T Eisenhoffer
- Graduate Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA.,Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.,Graduate School of Biomedical Sciences, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Alejandra Medina-Rivera
- Genetics and Genome Biology, Hospital for Sick Children, Toronto M5G 0A4, Canada.,Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Querétaro 76230, México
| | - Michael D Wilson
- Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Toronto M5S 3H2, Canada.,Genetics and Genome Biology, Hospital for Sick Children, Toronto M5G 0A4, Canada.,Department of Molecular Genetics, University of Toronto, Toronto M5S 1A8, Canada
| | - Joshua D Wythe
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX 77030, USA .,Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030, USA.,Graduate Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA
| |
Collapse
|
15
|
Abstract
The ETV6 (also known as TEL) gene encodes a transcriptional repressor that plays a critical role in hematopoiesis and in embryonic development. While somatic ETV6 translocations and missense mutations are frequently observed in human cancers, the role of ETV6 in malignant transformation was unclear. Recently, autosomal dominant germline ETV6 mutations were discovered in families with inherited thrombocytopenia and a propensity to develop hematological malignancy, unequivocally demonstrating a role for ETV6 in leukemogenesis. Studies of germline ETV6 mutations also uncovered an important function of ETV6 in megakaryocyte development. Here we discuss our current understanding of the role of ETV6 in malignancy and in hematopoiesis.
Collapse
Affiliation(s)
- Hanno Hock
- Cancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, and Harvard Stem Cell Institute, Boston, MA.
| | - Akiko Shimamura
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.
| |
Collapse
|
16
|
Tang J, Shen Y, Chen G, Wan Q, Wang K, Zhang J, Qin J, Liu G, Zuo S, Tao B, Yu Y, Wang J, Lazarus M, Yu Y. Activation of E-prostanoid 3 receptor in macrophages facilitates cardiac healing after myocardial infarction. Nat Commun 2017; 8:14656. [PMID: 28256515 PMCID: PMC5338035 DOI: 10.1038/ncomms14656] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Accepted: 01/16/2017] [Indexed: 02/07/2023] Open
Abstract
Two distinct monocyte (Mo)/macrophage (Mp) subsets (Ly6Clow and Ly6Chigh) orchestrate cardiac recovery process following myocardial infarction (MI). Prostaglandin (PG) E2 is involved in the Mo/Mp-mediated inflammatory response, however, the role of its receptors in Mos/Mps in cardiac healing remains to be determined. Here we show that pharmacological inhibition or gene ablation of the Ep3 receptor in mice suppresses accumulation of Ly6Clow Mos/Mps in infarcted hearts. Ep3 deletion in Mos/Mps markedly attenuates healing after MI by reducing neovascularization in peri-infarct zones. Ep3 deficiency diminishes CX3C chemokine receptor 1 (CX3CR1) expression and vascular endothelial growth factor (VEGF) secretion in Mos/Mps by suppressing TGFβ1 signalling and subsequently inhibits Ly6Clow Mos/Mps migration and angiogenesis. Targeted overexpression of Ep3 receptors in Mos/Mps improves wound healing by enhancing angiogenesis. Thus, the PGE2/Ep3 axis promotes cardiac healing after MI by activating reparative Ly6Clow Mos/Mps, indicating that Ep3 receptor activation may be a promising therapeutic target for acute MI. Acute myocardial infarction (AMI) triggers sterile inflammatory reaction mediated by prostaglandin E2 (PGE2). Tang et al. show that the PGE2 via its receptor EP3 promotes cardiac healing after AMI by recruiting reparative Ly6Clow monocytes/macrophages, which is mediated by TGF-β-driven regulation of CX3CR1 expression and VEGF secretion.
Collapse
Affiliation(s)
- Juan Tang
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.,Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Yujun Shen
- Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Guilin Chen
- Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Qiangyou Wan
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China
| | - Kai Wang
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China
| | - Jian Zhang
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.,Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Jing Qin
- Center for Genomic Sciences, LKS Faculty of Medicine, The University of Hong Kong, 5 Sassoon Road, Hong Kong, SAR 999077, China.,School of Life Science, Chinese University of Hong Kong, Hong Kong, SAR 999077, China
| | - Guizhu Liu
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China
| | - Shengkai Zuo
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China
| | - Bo Tao
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China
| | - Yu Yu
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China
| | - Junwen Wang
- Center for Genomic Sciences, LKS Faculty of Medicine, The University of Hong Kong, 5 Sassoon Road, Hong Kong, SAR 999077, China.,Division of Biomedical Statistics and Informatics, Center for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona 85259, USA.,Department of Biomedical Informatics, Arizona State University, Scottsdale, Arizona 85259, USA
| | - Michael Lazarus
- International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba City, Ibaraki 305-8575, Japan
| | - Ying Yu
- Key Laboratory of Food Safety Research, CAS Center for Excellence in Molecular Cell Science, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.,Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| |
Collapse
|
17
|
Sacilotto N, Chouliaras KM, Nikitenko LL, Lu YW, Fritzsche M, Wallace MD, Nornes S, García-Moreno F, Payne S, Bridges E, Liu K, Biggs D, Ratnayaka I, Herbert SP, Molnár Z, Harris AL, Davies B, Bond GL, Bou-Gharios G, Schwarz JJ, De Val S. MEF2 transcription factors are key regulators of sprouting angiogenesis. Genes Dev 2016; 30:2297-2309. [PMID: 27898394 PMCID: PMC5110996 DOI: 10.1101/gad.290619.116] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Accepted: 09/29/2016] [Indexed: 12/24/2022]
Abstract
Angiogenesis, the fundamental process by which new blood vessels form from existing ones, depends on precise spatial and temporal gene expression within specific compartments of the endothelium. However, the molecular links between proangiogenic signals and downstream gene expression remain unclear. During sprouting angiogenesis, the specification of endothelial cells into the tip cells that lead new blood vessel sprouts is coordinated by vascular endothelial growth factor A (VEGFA) and Delta-like ligand 4 (Dll4)/Notch signaling and requires high levels of Notch ligand DLL4. Here, we identify MEF2 transcription factors as crucial regulators of sprouting angiogenesis directly downstream from VEGFA. Through the characterization of a Dll4 enhancer directing expression to endothelial cells at the angiogenic front, we found that MEF2 factors directly transcriptionally activate the expression of Dll4 and many other key genes up-regulated during sprouting angiogenesis in both physiological and tumor vascularization. Unlike ETS-mediated regulation, MEF2-binding motifs are not ubiquitous to all endothelial gene enhancers and promoters but are instead overrepresented around genes associated with sprouting angiogenesis. MEF2 target gene activation is directly linked to VEGFA-induced release of repressive histone deacetylases and concurrent recruitment of the histone acetyltransferase EP300 to MEF2 target gene regulatory elements, thus establishing MEF2 factors as the transcriptional effectors of VEGFA signaling during angiogenesis.
Collapse
Affiliation(s)
- Natalia Sacilotto
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - Kira M Chouliaras
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - Leonid L Nikitenko
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - Yao Wei Lu
- Center for Cardiovascular Sciences, Albany Medical College, Albany, New York 12208, USA
| | - Martin Fritzsche
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - Marsha D Wallace
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - Svanhild Nornes
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - Fernando García-Moreno
- Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3QX, United Kingdom
| | - Sophie Payne
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - Esther Bridges
- Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 7LJ, United Kingdom
| | - Ke Liu
- Institute of Aging and Chronic Disease, University of Liverpool, Liverpool L7 8TX, United Kingdom
| | - Daniel Biggs
- The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom
| | - Indrika Ratnayaka
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - Shane P Herbert
- Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom
| | - Zoltán Molnár
- Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3QX, United Kingdom
| | - Adrian L Harris
- Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 7LJ, United Kingdom
| | - Benjamin Davies
- The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom
| | - Gareth L Bond
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| | - George Bou-Gharios
- Institute of Aging and Chronic Disease, University of Liverpool, Liverpool L7 8TX, United Kingdom
| | - John J Schwarz
- Center for Cardiovascular Sciences, Albany Medical College, Albany, New York 12208, USA
| | - Sarah De Val
- Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom
| |
Collapse
|
18
|
Craig MP, Sumanas S. ETS transcription factors in embryonic vascular development. Angiogenesis 2016; 19:275-85. [PMID: 27126901 DOI: 10.1007/s10456-016-9511-z] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 04/19/2016] [Indexed: 11/25/2022]
Abstract
At least thirteen ETS-domain transcription factors are expressed during embryonic hematopoietic or vascular development and potentially function in the formation and maintenance of the embryonic vasculature or blood lineages. This review summarizes our current understanding of the specific roles played by ETS factors in vasculogenesis and angiogenesis and the implications of functional redundancies between them.
Collapse
Affiliation(s)
- Michael P Craig
- Department of Biochemistry and Molecular Biology, Wright State University, 3640 Colonel Glenn Hwy., Dayton, OH, 45435, USA.,Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA
| | - Saulius Sumanas
- Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
| |
Collapse
|
19
|
Gubernator M, Slater SC, Spencer HL, Spiteri I, Sottoriva A, Riu F, Rowlinson J, Avolio E, Katare R, Mangialardi G, Oikawa A, Reni C, Campagnolo P, Spinetti G, Touloumis A, Tavaré S, Prandi F, Pesce M, Hofner M, Klemens V, Emanueli C, Angelini G, Madeddu P. Epigenetic profile of human adventitial progenitor cells correlates with therapeutic outcomes in a mouse model of limb ischemia. Arterioscler Thromb Vasc Biol 2015; 35:675-88. [PMID: 25573856 DOI: 10.1161/atvbaha.114.304989] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVE We investigated the association between the functional, epigenetic, and expressional profile of human adventitial progenitor cells (APCs) and therapeutic activity in a model of limb ischemia. APPROACH AND RESULTS Antigenic and functional features were analyzed throughout passaging in 15 saphenous vein (SV)-derived APC lines, of which 10 from SV leftovers of coronary artery bypass graft surgery and 5 from varicose SV removal. Moreover, 5 SV-APC lines were transplanted (8×10(5) cells, IM) in mice with limb ischemia. Blood flow and capillary and arteriole density were correlated with functional characteristics and DNA methylation/expressional markers of transplanted cells. We report successful expansion of tested lines, which reached the therapeutic target of 30 to 50 million cells in ≈10 weeks. Typical antigenic profile, viability, and migratory and proangiogenic activities were conserved through passaging, with low levels of replicative senescence. In vivo, SV-APC transplantation improved blood flow recovery and revascularization of ischemic limbs. Whole genome screening showed an association between DNA methylation at the promoter or gene body level and microvascular density and to a lesser extent with blood flow recovery. Expressional studies highlighted the implication of an angiogenic network centered on the vascular endothelial growth factor receptor as a predictor of microvascular outcomes. FLT-1 gene silencing in SV-APCs remarkably reduced their ability to form tubes in vitro and support tube formation by human umbilical vein endothelial cells, thus confirming the importance of this signaling in SV-APC angiogenic function. CONCLUSIONS DNA methylation landscape illustrates different therapeutic activities of human APCs. Epigenetic screening may help identify determinants of therapeutic vasculogenesis in ischemic disease.
Collapse
Affiliation(s)
- Miriam Gubernator
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Sadie C Slater
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Helen L Spencer
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Inmaculada Spiteri
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Andrea Sottoriva
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Federica Riu
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Jonathan Rowlinson
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Elisa Avolio
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Rajesh Katare
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Giuseppe Mangialardi
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Atsuhiko Oikawa
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Carlotta Reni
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Paola Campagnolo
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Gaia Spinetti
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Anestis Touloumis
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Simon Tavaré
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Francesca Prandi
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Maurizio Pesce
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Manuela Hofner
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Vierlinger Klemens
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Costanza Emanueli
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Gianni Angelini
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.)
| | - Paolo Madeddu
- From the Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK (M.G., S.C.S., H.L.S., F.R., J.R., E.A., R.K., G.M., A.O., C.R., C.E., G.A., P.M.); The Institute of Cancer Research, Evolutionary Genomics and Modelling Team, Centre for Evolution and Cancer, Sutton, UK (I.S., A.S.); Imperial College, London, UK (P.C., C.E., G.A.); MultiMedica Research Institute, Milan, Italy (G.S.); Cancer Research UK Cambridge Institute, Cambridge, UK (A.T., S.T.); Centro Cardiologico Monzino, Milan, Italy (F.P., M.P.); and Austrian Institute of Technology, Vienna, Austria (M.H., V.K.).
| |
Collapse
|
20
|
Rasighaemi P, Onnebo SMN, Liongue C, Ward AC. ETV6 (TEL1) regulates embryonic hematopoiesis in zebrafish. Haematologica 2014; 100:23-31. [PMID: 25281506 DOI: 10.3324/haematol.2014.104091] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Chromosomal translocations involving fusions of the human ETV6 (TEL1) gene occur frequently in hematologic malignancies. However, a detailed understanding of the normal function of ETV6 remains incomplete. This study has employed zebrafish as a relevant model to investigate the role of ETV6 during embryonic hematopoiesis. Zebrafish possessed a single conserved etv6 ortholog that was expressed from 12 hpf in the lateral plate mesoderm, and later in hematopoietic, vascular and other tissues. Morpholino-mediated gene knockdown of etv6 revealed the complex contribution of this gene toward embryonic hematopoiesis. During primitive hematopoiesis, etv6 knockdown resulted in reduced levels of progenitor cells, erythrocyte and macrophage populations, but increased numbers of incompletely differentiated heterophils. Definitive hematopoiesis was also perturbed, with etv6 knockdown leading to decreased erythrocytes and myeloid cells, but enhanced lymphopoiesis. This study suggests that ETV6 plays a broader and more complex role in early hematopoiesis than previously thought, impacting on the development of multiple lineages.
Collapse
Affiliation(s)
- Parisa Rasighaemi
- School of Medicine, and Strategic Research Centre in Molecular and Medical Research, Deakin University, Geelong
| | - Sara M N Onnebo
- School of Life & Environmental Sciences, Deakin University, Burwood, Victoria, Australia
| | - Clifford Liongue
- School of Medicine, and Strategic Research Centre in Molecular and Medical Research, Deakin University, Geelong
| | - Alister C Ward
- School of Medicine, and Strategic Research Centre in Molecular and Medical Research, Deakin University, Geelong
| |
Collapse
|
21
|
Alic N, Giannakou ME, Papatheodorou I, Hoddinott MP, Andrews TD, Bolukbasi E, Partridge L. Interplay of dFOXO and two ETS-family transcription factors determines lifespan in Drosophila melanogaster. PLoS Genet 2014; 10:e1004619. [PMID: 25232726 PMCID: PMC4169242 DOI: 10.1371/journal.pgen.1004619] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Accepted: 07/19/2014] [Indexed: 01/10/2023] Open
Abstract
Forkhead box O (FoxO) transcription factors (TFs) are key drivers of complex transcriptional programmes that determine animal lifespan. FoxOs regulate a number of other TFs, but how these TFs in turn might mediate the anti-ageing programmes orchestrated by FoxOs in vivo is unclear. Here, we identify an E-twenty six (ETS)-family transcriptional repressor, Anterior open (Aop), as regulated by the single Drosophila melanogaster FoxO (dFOXO) in the adult gut. AOP, the functional orthologue of the human Etv6/Tel protein, binds numerous genomic sites also occupied by dFOXO and counteracts the activity of an ETS activator, Pointed (Pnt), to prevent the lifespan-shortening effects of co-activation of dFOXO and PNT. This detrimental synergistic effect of dFOXO and PNT appears to stem from a mis-regulation of lipid metabolism. At the same time, AOP activity in another fly organ, the fat body, has further beneficial roles, regulating genes in common with dfoxo, such as the secreted, non-sensory, odorant binding protein (Obp99b), and robustly extending lifespan. Our study reveals a complex interplay between evolutionarily conserved ETS factors and dFOXO, the functional significance of which may extend well beyond animal lifespan. Despite the apparent complexity of ageing, animal lifespan can be extended. Activity of Forkhead Box O (FoxO) transcription factors can prolong survival of organisms ranging from the budding yeast to the fruit fly, and FoxO gene variants are linked to human longevity. FoxOs extend lifespan by driving complex, widespread changes in gene expression. Their primary targets include a second tier of transcriptional regulators, but it remains unclear how these secondary regulators are involved in the anti-ageing programmes orchestrated by FoxOs in vivo. To elucidate the role of this second tier, we identify a transcription factor called Anterior open (Aop) as directly regulated by the single Drosophila melanogaster FoxO protein (dFOXO) in the adult fly gut. Under certain circumstances, such as co-activation of the Pointed (PNT) transcription factor, dFOXO can be detrimental to lifespan. The role of Aop is to protect from this negative synergistic effect. Additionally, activation of AOP in the fly adipose tissue can robustly extend lifespan. Our study reveals a complex interplay between two evolutionarily conserved transcriptional regulators and dFOXO in lifespan. This significance of this interplay may extend to other physiological processes where these transcription factors play important roles.
Collapse
Affiliation(s)
- Nazif Alic
- Institute of Healthy Ageing, and GEE, University College London, London, United Kingdom
| | - Maria E. Giannakou
- Institute of Healthy Ageing, and GEE, University College London, London, United Kingdom
| | - Irene Papatheodorou
- Institute of Healthy Ageing, and GEE, University College London, London, United Kingdom
- EMBL - European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom
| | - Matthew P. Hoddinott
- Institute of Healthy Ageing, and GEE, University College London, London, United Kingdom
- Max Planck Institute for Biology of Ageing, Cologne, Germany
| | - T. Daniel Andrews
- EMBL - European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom
| | - Ekin Bolukbasi
- Institute of Healthy Ageing, and GEE, University College London, London, United Kingdom
- Max Planck Institute for Biology of Ageing, Cologne, Germany
| | - Linda Partridge
- Institute of Healthy Ageing, and GEE, University College London, London, United Kingdom
- Max Planck Institute for Biology of Ageing, Cologne, Germany
- * E-mail:
| |
Collapse
|
22
|
Caviglia S, Luschnig S. Tube fusion: Making connections in branched tubular networks. Semin Cell Dev Biol 2014; 31:82-90. [DOI: 10.1016/j.semcdb.2014.03.018] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2014] [Revised: 03/03/2014] [Accepted: 03/14/2014] [Indexed: 11/16/2022]
|
23
|
Deng H, Li F, Li H, Deng Y, Liu J, Wang D, Han G, Wang XJ, Zhang Q. CtBP1 overexpression in keratinocytes perturbs skin homeostasis. J Invest Dermatol 2013; 134:1323-1331. [PMID: 24280726 PMCID: PMC4537778 DOI: 10.1038/jid.2013.504] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Revised: 09/24/2013] [Accepted: 10/08/2013] [Indexed: 12/20/2022]
Abstract
Carboxyl-terminal binding protein-1 (CtBP1) is a transcriptional co-repressor with multiple in vitro targets, but its in vivo functions are largely unknown. We generated keratinocyte-specific CtBP1 transgenic mice with a keratin 5 promoter (K5.CtBP1) to probe the pathological roles of CtBP1. At transgene expression levels comparable with endogenous CtBP1 in acute skin wounds, K5.CtBP1 epidermis displayed hyperproliferation, loss of E-cadherin, and failed terminal differentiation. Known CtBP1 target genes associated with these processes, e.g., p21, Brca1, and E-cadherin were down-regulated in K5.CtBP1 skin. Surprisingly, K5.CtBP1 pups also exhibited a hair loss phenotype. We found that expression of the Distal-less 3 (Dlx3), a critical regulator of hair follicle differentiation and cycling, was decreased in K5.CtBP1 mice. Molecular studies revealed that CtBP1 directly suppressed Dlx3 transcription. Consistently, K5.CtBP1 mice displayed abnormal hair follicles with decreased expression of Dlx3 downstream targets Gata3, Hoxc13, and hair keratins. In sum, this first CtBP1 transgenic model provides in vivo evidence for certain CtBP1 functions predicted from in vitro studies, reveals to our knowledge previously unreported functions and transcriptional activities of CtBP1 in the context of epithelial-mesenchymal interplay, and suggest CtBP1 has a pathogenesis role in hair follicle morphogenesis and differentiation.
Collapse
Affiliation(s)
- Hui Deng
- Department of Dermatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Pathology, University of Colorado Denver, Aurora, Colorado, USA; Department of Dermatology, The Sixth People's Hospital of Shanghai, Shanghai Jiaotong University, Shanghai, China
| | - Fulun Li
- Department of Pathology, University of Colorado Denver, Aurora, Colorado, USA; Department of Dermatology, Yueyang Hospital Affiliated to Shanghai University of TCM, Shanghai, China
| | - Hong Li
- Department of Dermatology, University of Colorado Denver, Aurora, Colorado, USA
| | - Yu Deng
- Department of Dermatology, University of Colorado Denver, Aurora, Colorado, USA
| | - Jing Liu
- Department of Dermatology, University of Colorado Denver, Aurora, Colorado, USA
| | - Donna Wang
- Department of Pathology, University of Colorado Denver, Aurora, Colorado, USA.
| | - Gangwen Han
- Department of Pathology, University of Colorado Denver, Aurora, Colorado, USA
| | - Xiao-Jing Wang
- Department of Dermatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Pathology, University of Colorado Denver, Aurora, Colorado, USA.
| | - Qinghong Zhang
- Department of Dermatology, University of Colorado Denver, Aurora, Colorado, USA; Department of Pathology, University of Colorado Denver, Aurora, Colorado, USA; Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, Colorado, USA
| |
Collapse
|
24
|
Cama A, Verginelli F, Lotti LV, Napolitano F, Morgano A, D’Orazio A, Vacca M, Perconti S, Pepe F, Romani F, Vitullo F, di Lella F, Visone R, Mannelli M, Neumann HPH, Raiconi G, Paties C, Moschetta A, Tagliaferri R, Veronese A, Sanna M, Mariani-Costantini R. Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling. Acta Neuropathol 2013; 126:575-94. [PMID: 23955600 PMCID: PMC3789891 DOI: 10.1007/s00401-013-1165-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Accepted: 08/02/2013] [Indexed: 02/06/2023]
Abstract
Head and neck paragangliomas, rare neoplasms of the paraganglia composed of nests of neurosecretory and glial cells embedded in vascular stroma, provide a remarkable example of organoid tumor architecture. To identify genes and pathways commonly deregulated in head and neck paraganglioma, we integrated high-density genome-wide copy number variation (CNV) analysis with microRNA and immunomorphological studies. Gene-centric CNV analysis of 24 cases identified a list of 104 genes most significantly targeted by tumor-associated alterations. The "NOTCH signaling pathway" was the most significantly enriched term in the list (P = 0.002 after Bonferroni or Benjamini correction). Expression of the relevant NOTCH pathway proteins in sustentacular (glial), chief (neuroendocrine) and endothelial cells was confirmed by immunohistochemistry in 47 head and neck paraganglioma cases. There were no relationships between level and pattern of NOTCH1/JAG2 protein expression and germline mutation status in the SDH genes, implicated in paraganglioma predisposition, or the presence/absence of immunostaining for SDHB, a surrogate marker of SDH mutations. Interestingly, NOTCH upregulation was observed also in cases with no evidence of CNVs at NOTCH signaling genes, suggesting altered epigenetic modulation of this pathway. To address this issue we performed microarray-based microRNA expression analyses. Notably 5 microRNAs (miR-200a,b,c and miR-34b,c), including those most downregulated in the tumors, correlated to NOTCH signaling and directly targeted NOTCH1 in in vitro experiments using SH-SY5Y neuroblastoma cells. Furthermore, lentiviral transduction of miR-200s and miR-34s in patient-derived primary tympano-jugular paraganglioma cell cultures was associated with NOTCH1 downregulation and increased levels of markers of cell toxicity and cell death. Taken together, our results provide an integrated view of common molecular alterations associated with head and neck paraganglioma and reveal an essential role of NOTCH pathway deregulation in this tumor type.
Collapse
Affiliation(s)
- Alessandro Cama
- Unit of General Pathology, Aging Research Center (Ce.S.I.), G. d’Annunzio University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
- Department of Pharmacy, G. d’Annunzio University, Via dei Vestini 1, 66100 Chieti, Italy
| | - Fabio Verginelli
- Unit of General Pathology, Aging Research Center (Ce.S.I.), G. d’Annunzio University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
- Department of Pharmacy, G. d’Annunzio University, Via dei Vestini 1, 66100 Chieti, Italy
| | - Lavinia Vittoria Lotti
- Department of Experimental Medicine, University La Sapienza, Viale Regina Elena 324, 00161 Rome, Italy
| | - Francesco Napolitano
- NeuRoNe Lab, Department of Informatics, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno Italy
| | - Annalisa Morgano
- Unit of General Pathology, Aging Research Center (Ce.S.I.), G. d’Annunzio University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
- Laboratory of Lipid Metabolism and Cancer, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Via Nazionale 8/A, 66030 Santa Maria Imbaro, Chieti Italy
| | - Andria D’Orazio
- Laboratory of Lipid Metabolism and Cancer, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Via Nazionale 8/A, 66030 Santa Maria Imbaro, Chieti Italy
| | - Michele Vacca
- Laboratory of Lipid Metabolism and Cancer, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Via Nazionale 8/A, 66030 Santa Maria Imbaro, Chieti Italy
- IRCCS National Cancer Research Center Giovanni Paolo II, Viale Orazio Flacco 65, 70124 Bari, Italy
| | - Silvia Perconti
- Unit of General Pathology, Aging Research Center (Ce.S.I.), G. d’Annunzio University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
- Department of Pharmacy, G. d’Annunzio University, Via dei Vestini 1, 66100 Chieti, Italy
| | - Felice Pepe
- Unit of General Pathology, Aging Research Center (Ce.S.I.), G. d’Annunzio University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
- NeuRoNe Lab, Department of Informatics, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno Italy
| | - Federico Romani
- Department of Experimental Medicine, University La Sapienza, Viale Regina Elena 324, 00161 Rome, Italy
| | | | | | - Rosa Visone
- Unit of General Pathology, Aging Research Center (Ce.S.I.), G. d’Annunzio University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
- Department of Medical, Oral and Biotechnological Sciences, G. d’Annunzio University, Via dei Vestini 1, 66100 Chieti, Italy
| | - Massimo Mannelli
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134 Florence, Italy
| | - Hartmut P. H. Neumann
- Section of Preventive Medicine, Department of Nephrology, Albert-Ludwigs-University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
| | - Giancarlo Raiconi
- NeuRoNe Lab, Department of Informatics, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno Italy
| | - Carlo Paties
- Unit of Anatomic Pathology, Department of Clinical Pathology, Hospital G. da Saliceto, Via Giuseppe Taverna 49, 29100 Piacenza, Italy
| | - Antonio Moschetta
- Laboratory of Lipid Metabolism and Cancer, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Via Nazionale 8/A, 66030 Santa Maria Imbaro, Chieti Italy
- IRCCS National Cancer Research Center Giovanni Paolo II, Viale Orazio Flacco 65, 70124 Bari, Italy
| | - Roberto Tagliaferri
- NeuRoNe Lab, Department of Informatics, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno Italy
| | - Angelo Veronese
- Unit of General Pathology, Aging Research Center (Ce.S.I.), G. d’Annunzio University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
- Department of Medical, Oral and Biotechnological Sciences, G. d’Annunzio University, Via dei Vestini 1, 66100 Chieti, Italy
| | - Mario Sanna
- Gruppo Otologico, Via Emmanueli 42, 29100 Piacenza, Italy
- Department of Medical, Oral and Biotechnological Sciences, G. d’Annunzio University, Via dei Vestini 1, 66100 Chieti, Italy
| | - Renato Mariani-Costantini
- Unit of General Pathology, Aging Research Center (Ce.S.I.), G. d’Annunzio University Foundation, Via Colle dell’Ara, 66100 Chieti, Italy
- Department of Medical, Oral and Biotechnological Sciences, G. d’Annunzio University, Via dei Vestini 1, 66100 Chieti, Italy
| |
Collapse
|
25
|
Wu SP, Dong XR, Regan JN, Su C, Majesky MW. Tbx18 regulates development of the epicardium and coronary vessels. Dev Biol 2013; 383:307-20. [PMID: 24016759 DOI: 10.1016/j.ydbio.2013.08.019] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2013] [Revised: 08/21/2013] [Accepted: 08/21/2013] [Indexed: 11/16/2022]
Abstract
The epicardium and coronary vessels originate from progenitor cells in the proepicardium. Here we show that Tbx18, a T-box family member highly expressed in the proepicardium, controls critical early steps in coronary development. In Tbx18(-/-) mouse embryos, both the epicardium and coronary vessels exhibit structural and functional defects. At E12.5, the Tbx18-deficient epicardium contains protrusions and cyst-like structures overlying a disorganized coronary vascular plexus that contains ectopic structures resembling blood islands. At E13.5, the left and right coronary stems form correctly in mutant hearts. However, analysis of PECAM-1 whole mount immunostaining, distribution of SM22α(lacZ/+) activity, and analysis of coronary vascular casts suggest that defective vascular plexus remodeling produces a compromised arterial network at birth consisting of fewer distributing conduit arteries with smaller lumens and a reduced capacity to conduct blood flow. Gene expression profiles of Tbx18(-/-) hearts at E12.5 reveal altered expression of 79 genes that are associated with development of the vascular system including sonic hedgehog signaling components patched and smoothened, VEGF-A, angiopoietin-1, endoglin, and Wnt factors compared to wild type hearts. Thus, formation of coronary vasculature is responsive to Tbx18-dependent gene targets in the epicardium, and a poorly structured network of coronary conduit vessels is formed in Tbx18 null hearts due to defects in epicardial cell signaling and fate during heart development. Lastly, we demonstrate that Tbx18 possesses a SRF/CArG box dependent repressor activity capable of inhibiting progenitor cell differentiation into smooth muscle cells, suggesting a potential function of Tbx18 in maintaining the progenitor status of epicardial-derived cells.
Collapse
Affiliation(s)
- San-Pin Wu
- Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX 77030, United States.
| | | | | | | | | |
Collapse
|
26
|
C-Terminal Binding Protein: A Molecular Link between Metabolic Imbalance and Epigenetic Regulation in Breast Cancer. Int J Cell Biol 2013; 2013:647975. [PMID: 23762064 PMCID: PMC3671672 DOI: 10.1155/2013/647975] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2012] [Revised: 04/14/2013] [Accepted: 04/15/2013] [Indexed: 12/21/2022] Open
Abstract
The prevalence of obesity has given rise to significant global concerns as numerous population-based studies demonstrate an incontrovertible association between obesity and breast cancer. Mechanisms proposed to account for this linkage include exaggerated levels of carbohydrate substrates, elevated levels of circulating mitogenic hormones, and inflammatory cytokines that impinge on epithelial programming in many tissues. Moreover, recently many scientists have rediscovered the observation, first described by Otto Warburg nearly a century ago, that most cancer cells undergo a dramatic metabolic shift in energy utilization and expenditure that fuels and supports the cellular expansion associated with malignant proliferation. This shift in substrate oxidation comes at the cost of sharp changes in the levels of the high energy intermediate, nicotinamide adenine dinucleotide (NADH). In this review, we discuss a novel example of how shifts in the concentration and flux of substrates metabolized and generated during carbohydrate metabolism represent components of a signaling network that can influence epigenetic regulatory events in the nucleus. We refer to this regulatory process as "metabolic transduction" and describe how the C-terminal binding protein (CtBP) family of NADH-dependent nuclear regulators represents a primary example of how cellular metabolic status can influence epigenetic control of cellular function and fate.
Collapse
|
27
|
Protein kinase D2 and heat shock protein 90 beta are required for BCL6-associated zinc finger protein mRNA stabilization induced by vascular endothelial growth factor-A. Angiogenesis 2013; 16:675-88. [DOI: 10.1007/s10456-013-9345-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Accepted: 03/08/2013] [Indexed: 10/27/2022]
|
28
|
Siekmann AF, Affolter M, Belting HG. The tip cell concept 10 years after: new players tune in for a common theme. Exp Cell Res 2013; 319:1255-63. [PMID: 23419245 DOI: 10.1016/j.yexcr.2013.01.019] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2013] [Accepted: 01/31/2013] [Indexed: 01/24/2023]
Affiliation(s)
- Arndt F Siekmann
- Max Planck Institute for Molecular Biomedicine, D-48149 Muenster, Germany.
| | | | | |
Collapse
|
29
|
Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med 2013; 3:a006569. [PMID: 23085847 DOI: 10.1101/cshperspect.a006569] [Citation(s) in RCA: 384] [Impact Index Per Article: 34.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Sprouting angiogenesis is a dynamic process in which endothelial cells collectively migrate, shape new lumenized tubes, make new connections, and remodel the nascent network into a hierarchically branched and functionally perfused vascular bed. Endothelial cells in the nascent sprout adopt two distinct cellular phenotypes--known as tip and stalk cells--with specialized functions and gene expression patterns. VEGF and Notch signaling engage in an intricate cross talk to balance tip and stalk cell formation and to regulate directed tip cell migration and stalk cell proliferation. In this article, we summarize the current knowledge and implications of the tip/stalk cell concepts and the quantitative and dynamic integration of VEGF and Notch signaling in tip and stalk cell selection.
Collapse
Affiliation(s)
- Raquel Blanco
- Vascular Biology Laboratory, London Research Institute, Lincoln's Inn Fields Laboratories, London WC2A 3LY, UK
| | | |
Collapse
|
30
|
Regulation of endothelial and hematopoietic development by the ETS transcription factor Etv2. Curr Opin Hematol 2012; 19:199-205. [PMID: 22406820 DOI: 10.1097/moh.0b013e3283523e07] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
PURPOSE OF REVIEW Vasculogenesis and hematopoiesis are essential for development. Recently, the ETS domain transcription factor Etv2 has been identified as an essential regulator of vasculogenesis and hematopoiesis. Here, we review the recent studies that have established the critical role of Etv2 in the specification of mesoderm to blood and endothelial cells. RECENT FINDINGS Loss and gain-of-function studies have demonstrated the conserved role of Etv2 in endothelial and hematopoietic development. Recent studies have placed Etv2 at or near the top of the hierarchy in specification of these lineages and have begun to dissect the upstream regulators and downstream effectors of Etv2 function using multiple model organisms and experimental systems. SUMMARY Etv2 is essential for the specification of endothelial and hematopoietic lineages. Understanding the mechanisms through which Etv2 specifies endothelial and blood cells by defining upstream transcriptional regulators and cofactors will lead to greater insight into vasculogenesis and hematopoiesis, and may help to identify therapeutic targets to treat vascular disorders or to promote or inhibit vessel growth.
Collapse
|
31
|
In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A 2012; 109:9342-7. [PMID: 22645376 DOI: 10.1073/pnas.1201240109] [Citation(s) in RCA: 620] [Impact Index Per Article: 51.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Microvascular networks support metabolic activity and define microenvironmental conditions within tissues in health and pathology. Recapitulation of functional microvascular structures in vitro could provide a platform for the study of complex vascular phenomena, including angiogenesis and thrombosis. We have engineered living microvascular networks in three-dimensional tissue scaffolds and demonstrated their biofunctionality in vitro. We describe the lithographic technique used to form endothelialized microfluidic vessels within a native collagen matrix; we characterize the morphology, mass transfer processes, and long-term stability of the endothelium; we elucidate the angiogenic activities of the endothelia and differential interactions with perivascular cells seeded in the collagen bulk; and we demonstrate the nonthrombotic nature of the vascular endothelium and its transition to a prothrombotic state during an inflammatory response. The success of these microvascular networks in recapitulating these phenomena points to the broad potential of this platform for the study of cardiovascular biology and pathophysiology.
Collapse
|
32
|
New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis. Biochem Soc Trans 2012; 39:1612-8. [PMID: 22103496 DOI: 10.1042/bst20110721] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Notch signalling is a key pathway controlling angiogenesis in normal tissues and tumours. This has become a major focus of development of anticancer therapy, but to develop this appropriately, we need further understanding of the mechanisms of regulation of Dll4 (Delta-like ligand 4), a key endothelial Notch ligand. Dll4 and VEGF (vascular endothelial growth factor) cross-talk, with VEGF up-regulation of Dll4 and Dll4 down-regulating VEGFR (VEGF receptor) signalling. Both are essential for normal angiogenesis, and blockade of one may produce compensatory changes in the other. The present review considers recent developments in the regulation of Dll4 expression and functions, its role as a mechanism of resistance to anti-angiogenic therapy, and methods needed to develop effective therapy against this target.
Collapse
|
33
|
BAZF, a novel component of cullin3-based E3 ligase complex, mediates VEGFR and Notch cross-signaling in angiogenesis. Blood 2012; 119:2688-98. [PMID: 22279058 DOI: 10.1182/blood-2011-03-345306] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Angiogenic homeostasis is maintained by a balance between vascular endothelial growth factor (VEGF) and Notch signaling in endothelial cells (ECs). We screened for molecules that might mediate the coupling of VEGF signal transduction with down-regulation of Notch signaling, and identified B-cell chronic lymphocytic leukemia/lymphoma6-associated zinc finger protein (BAZF). BAZF was induced by VEGF-A in ECs to bind to the Notch signaling factor C-promoter binding factor 1 (CBF1), and to promote the degradation of CBF1 through polyubiquitination in a CBF1-cullin3 (CUL3) E3 ligase complex. BAZF disruption in vivo decreased endothelial tip cell number and filopodia protrusion, and markedly abrogated vascular plexus formation in the mouse retina, overlapping the retinal phenotype seen in response to Notch activation. Further, impaired angiogenesis and capillary remodeling were observed in skin-wounded BAZF(-/-) mice. We therefore propose that BAZF supports angiogenic sprouting via BAZF-CUL3-based polyubiquitination-dependent degradation of CBF1 to down-regulate Notch signaling.
Collapse
|
34
|
Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146:873-87. [PMID: 21925313 DOI: 10.1016/j.cell.2011.08.039] [Citation(s) in RCA: 1994] [Impact Index Per Article: 153.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2011] [Revised: 07/12/2011] [Accepted: 08/29/2011] [Indexed: 12/18/2022]
Abstract
Blood vessels form extensive networks that nurture all tissues in the body. Abnormal vessel growth and function are hallmarks of cancer and ischemic and inflammatory diseases, and they contribute to disease progression. Therapeutic approaches to block vascular supply have reached the clinic, but limited efficacy and resistance pose unresolved challenges. Recent insights establish how endothelial cells communicate with each other and with their environment to form a branched vascular network. The emerging principles of vascular growth provide exciting new perspectives, the translation of which might overcome the current limitations of pro- and antiangiogenic medicine.
Collapse
Affiliation(s)
- Michael Potente
- Vascular Epigenetics Group, Institute for Cardiovascular Regeneration, Center of Molecular Medicine, Goethe University, D-60590 Frankfurt, Germany
| | | | | |
Collapse
|
35
|
Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011; 12:551-64. [PMID: 21860391 PMCID: PMC3319719 DOI: 10.1038/nrm3176] [Citation(s) in RCA: 746] [Impact Index Per Article: 57.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The vertebrate vasculature forms an extensive branched network of blood vessels that supplies tissues with nutrients and oxygen. During vascular development, coordinated control of endothelial cell behaviour at the levels of cell migration, proliferation, polarity, differentiation and cell-cell communication is critical for functional blood vessel morphogenesis. Recent data uncover elaborate transcriptional, post-transcriptional and post-translational mechanisms that fine-tune key signalling pathways (such as the vascular endothelial growth factor and Notch pathways) to control endothelial cell behaviour during blood vessel sprouting (angiogenesis). These emerging frameworks controlling angiogenesis provide unique insights into fundamental biological processes common to other systems, such as tissue branching morphogenesis, mechanotransduction and tubulogenesis.
Collapse
Affiliation(s)
- Shane P. Herbert
- Department of Biochemistry and Biophysics, Programs in Developmental and Stem Cell Biology, Genetics and Human Genetics, Cardiovascular Research Institute, University of California, San Francisco, California 94158, USA
- Multidisciplinary Cardiovascular Research Centre and Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
- Faculty of Life Sciences, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK
| | - Didier Y.R. Stainier
- Department of Biochemistry and Biophysics, Programs in Developmental and Stem Cell Biology, Genetics and Human Genetics, Cardiovascular Research Institute, University of California, San Francisco, California 94158, USA
| |
Collapse
|
36
|
De Val S. Key transcriptional regulators of early vascular development. Arterioscler Thromb Vasc Biol 2011; 31:1469-75. [PMID: 21677289 DOI: 10.1161/atvbaha.110.221168] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The formation of the vasculature depends on the precise spatial and temporal control of gene expression to define endothelial cell identity and to ensure the correct distribution and structure of the forming vessel network. This review provides an overview of the establishment of the vascular system, accompanied by a detailed discussion of the transcription factors involved in regulating endothelial gene expression during vasculogenesis and early vessel formation in both fish and mammalian systems. We also review the transcriptional pathways lying both upstream and downstream of key vascular transcription factors.
Collapse
Affiliation(s)
- Sarah De Val
- Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, Old Road Campus Research Bldg, University of Oxford, Off Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
| |
Collapse
|
37
|
Zhang JP, Qin HY, Wang L, Liang L, Zhao XC, Cai WX, Wei YN, Wang CM, Han H. Overexpression of Notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization. Cancer Lett 2011; 309:220-7. [PMID: 21752535 DOI: 10.1016/j.canlet.2011.06.008] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2011] [Revised: 06/12/2011] [Accepted: 06/14/2011] [Indexed: 12/18/2022]
Abstract
Notch signaling plays an important role in vascular development and tumor angiogenesis. It has been shown that disruption of Dll4-triggered Notch signal activation effectively inhibits tumor growth, but this treatment also results in the formation of vascular neoplasms. In this study, we investigate the effects of over-expressing Notch ligand Dll1 in B16 melanoma cells on tumor cell proliferation and tumor growth in vitro and in vivo. Our results showed that over-expression of Dll1 could activate Notch signaling in tumor cells, and promote tumor cell proliferation in vitro. In contrast, growth of Dll1-over-expressing tumors in vivo was reduced, due to abnormal tumor vessel formation. Impaired tumor vasculature enhanced hypoxia and necrosis in tumor tissues, leading to retarded tumor growth. These results suggest that activation of Notch signaling may serve as an anti-angiogenesis strategy in the treatment of malignant tumors.
Collapse
Affiliation(s)
- Jian-Ping Zhang
- State Key Laboratory of Cancer Biology, Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xian 710032, China
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Estrach S, Cailleteau L, Franco CA, Gerhardt H, Stefani C, Lemichez E, Gagnoux-Palacios L, Meneguzzi G, Mettouchi A. Laminin-binding integrins induce Dll4 expression and Notch signaling in endothelial cells. Circ Res 2011; 109:172-82. [PMID: 21474814 DOI: 10.1161/circresaha.111.240622] [Citation(s) in RCA: 88] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
RATIONALE Integrins play a crucial role in controlling endothelial cell proliferation and migration during angiogenesis. The Delta-like 4 (Dll4)/Notch pathway establishes an adequate ratio between stalk and tip cell populations by restricting tip cell formation through "lateral inhibition" in response to a vascular endothelial growth factor gradient. Because angiogenesis requires a tight coordination of these cellular processes, we hypothesized that adhesion, vascular endothelial growth factor, and Notch signaling pathways are interconnected. OBJECTIVE This study was aimed at characterizing the cross-talk between integrin and Notch signaling in endothelial cells. METHODS AND RESULTS Adhesion of primary human endothelial cells to laminin-111 triggers Dll4 expression, leading to subsequent Notch pathway activation. SiRNA-mediated knockdown of α2β1 and α6β1 integrins abolishes Dll4 induction, which discloses a selective integrin signaling acting upstream of Notch pathway. The increase in Foxc2 transcription, triggered by α2β1 binding to laminin, is required but not sufficient per se for Dll4 expression. Furthermore, vascular endothelial growth factor stimulates laminin γ1 deposition, which leads to integrin signaling and Dll4 induction. Interestingly, loss of integrins α2 or α6 mimics the effects of Dll4 silencing and induces excessive network branching in an in vitro sprouting angiogenesis assay on three-dimensional matrigel. CONCLUSIONS We show that, in endothelial cells, ligation of α2β1 and α6β1 integrins induces the Notch pathway, and we disclose a novel role of basement membrane proteins in the processes controlling tip vs stalk cell selection.
Collapse
|
39
|
Whyte JL, Ball SG, Shuttleworth CA, Brennan K, Kielty CM. Density of human bone marrow stromal cells regulates commitment to vascular lineages. Stem Cell Res 2011; 6:238-50. [PMID: 21420373 PMCID: PMC3223522 DOI: 10.1016/j.scr.2011.02.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2010] [Revised: 02/04/2011] [Accepted: 02/09/2011] [Indexed: 02/06/2023] Open
Abstract
Mechanisms underlying the vascular differentiation of human bone marrow stromal cells (HBMSCs) and their contribution to neovascularisation are poorly understood. We report the essential role of cell density-induced signals in directing HBMSCs along endothelial or smooth muscle lineages. Plating HBMSCs at high density rapidly induced Notch signaling, which initiated HBMSC commitment to a vascular progenitor cell population expressing markers for both vascular lineages. Notch also induced VEGF-A, which inhibited vascular smooth muscle commitment while consolidating differentiation to endothelial cells with cobblestone morphology and characteristic endothelial markers and functions. These mechanisms can be exploited therapeutically to regulate HBMSCs during neovascularisation.
Collapse
Affiliation(s)
| | | | | | | | - Cay M. Kielty
- Corresponding author at: Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, UK. Fax: +44 161 275 5082.
| |
Collapse
|